Associations between gastro-oesophageal reflux, its management and exacerbations of chronic obstructive pulmonary disease

Respir Med. 2015 Sep;109(9):1147-54. doi: 10.1016/j.rmed.2015.06.009. Epub 2015 Jun 23.

Abstract

Aim: To determine factors, overall and by sex, associated with self-reported gastro-oesophageal reflux disease (GORD) in chronic obstructive pulmonary disease (COPD) patients, and to evaluate relationships between GORD, its modification by acid suppression medications (Proton Pump Inhibitors [PPI]/histamine-2 receptor antagonists [H2RA]) and exacerbations of COPD and mortality.

Methods: Logistic regression was used to determine factors associated with GORD; Cox proportional hazards models were used to calculate adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for GORD and risk of exacerbation and death.

Results: Among 2135 COPD patients from the ECLIPSE cohort, 547 patients self-reported GORD, with female preponderance; 237 were taking PPI/H2RA. Risk factors for GORD did not differ by sex. When compared to patients who did not report GORD or use of PPI/H2RA, patients with GORD and taking PPI/H2RA had a significantly increased risk of exacerbation (HR = 1.58, 95%CI = 1.35-1.86); risk was also increased for patients reporting GORD only or PPI/H2RA use only (HR = 1.21 [1.04-1.40] and 1.33 [1.08-1.65], respectively). Similar findings were observed for risk of hospitalised exacerbation. GORD was not associated with mortality.

Conclusion: GORD in COPD patients is highly prevalent, and risk factors did not differ by sex. Use of PPI/H2RA and self-reported GORD were associated with increased risk of moderate-to-severe and hospitalised exacerbations.

Keywords: Chronic obstructive pulmonary disease; Cohort study; Epidemiology; Gastro-oesophageal reflux disease.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Comorbidity
  • England / epidemiology
  • Gastroesophageal Reflux / drug therapy
  • Gastroesophageal Reflux / epidemiology*
  • Histamine H2 Antagonists / adverse effects
  • Histamine H2 Antagonists / therapeutic use
  • Hospitalization / statistics & numerical data
  • Humans
  • Kaplan-Meier Estimate
  • Middle Aged
  • Prevalence
  • Proton Pump Inhibitors / adverse effects
  • Proton Pump Inhibitors / therapeutic use
  • Pulmonary Disease, Chronic Obstructive / epidemiology*
  • Pulmonary Disease, Chronic Obstructive / etiology
  • Risk Factors
  • Sex Factors

Substances

  • Histamine H2 Antagonists
  • Proton Pump Inhibitors